Sandoz (SDZ.SW) confirmed its existing mid‑term outlook through 2028 and introduced a fresh guidance horizon covering 2025 to 2030. The company now targets average annual net‑sales growth of mid‑to‑high single‑digit percentages in constant currencies and a core EBITDA margin of 25‑27% by the end of the decade.
Under the newly announced Bio100 initiative, Sandoz plans to more than double net sales from 2025 levels by 2035 and lift its core EBITDA margin above 30% that year. The programme also sets a goal of building a portfolio of more than 100 biosimilars by 2040, up from the current 13, and increasing the share of sales covered by loss‑of‑exclusivity patents to roughly 80% from 2035 onward.
CEO Richard Saynor said the Bio100 ambitions are designed to make biosimilars the majority of the company’s revenue, expanding patient access while delivering value to shareholders. At the close of trading on the SIX Swiss Exchange, Sandoz shares were priced at 68.24 Swiss francs, down 0.18%.
